Angeloni N, McMahon K, Swaminathan S, Plebanek M, Osman I, Volpert O, et al. Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1. Sci Rep. 2016;6:22915 pubmed publisher

Zhu C, Bandekar A, Sempkowski M, Banerjee S, Pomper M, Bruchertseifer F, et al. Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues. Mol Cancer Ther. 2016;15:106-113 pubmed publisher

Rybalov M, Ananias H, Hoving H, van der Poel H, Rosati S, de Jong I. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci. 2014;15:6046-61 pubmed publisher

De Oliveira S, Wang J, Ryan C, Morrison S, Kohn D, Hollis R. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. J Transl Med. 2013;11:23 pubmed publisher

Morgenroth A, Tinkir E, Vogg A, Sankaranarayanan R, Baazaoui F, Mottaghy F. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Breast Cancer Res. 2019;21:116 pubmed publisher

Endepols H, Morgenroth A, Zlatopolskiy B, Krapf P, Zischler J, Richarz R, et al. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents. BMC Cancer. 2019;19:633 pubmed publisher

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss C, Eiber M, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159-175 pubmed publisher

Tao R, Ni Z, Liu C, Zhu M, Ji X, Chen X, et al. Expression, purification and identification of an immunogenic fragment in the ectodomain of prostate-specific membrane antigen. Exp Ther Med. 2016;11:747-752 pubmed

Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, et al. In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles. Int J Mol Sci. 2015;16:9573-87 pubmed publisher

Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, et al. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate. 2014;74:1674-90 pubmed publisher

Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol. 2014;31:857 pubmed publisher

Xu L, Wang Z, Li X, He X, Guan L, Tuo J, et al. Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. Oncol Rep. 2013;30:1920-8 pubmed publisher

Schol D, Fleron M, Greisch J, Jaeger M, Frenz M, De Pauw E, et al. Anti-PSMA antibody-coupled gold nanorods detection by optical and electron microscopies. Micron. 2013;50:68-74 pubmed publisher

Wang L, Li L, Guo Y, Tong H, Fan X, Ding J, et al. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer. Prostate. 2013;73:1147-58 pubmed publisher

Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, et al. Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate. 2013;73:835-41 pubmed publisher

Cao K, Xu L, Zhang D, Zhang X, Zhang T, He X, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40:1977-85 pubmed publisher

Qin B, Tai W, Shukla R, Cheng K. Identification of a LNCaP-specific binding peptide using phage display. Pharm Res. 2011;28:2422-34 pubmed publisher